索利那新联合坦索罗辛治疗膀胱过度活动症的疗效研究

目的探讨索利那新联合坦索罗辛治疗膀胱过度活动症(OAB)的临床疗效。方法 2010年9月-2011年9月收集贵州省人民医院泌尿外科及男科门诊的慢性前列腺炎伴OAB患者157例。患者口服盐酸莫西沙星0.4 g,每天1次,2周;同时服用坦索罗辛0.2 mg+索利那新5.0 mg,每天1次,4周。观察患者治疗前及治疗4周、停药4周前列腺液中WBC计数,OABSS评分(白天排尿次数、夜间排尿次数、尿急、急迫性尿失禁),NIH-CPSI评分、最大尿流率(Qmax)、每次排尿量,评估患者OAB症状的改善情况。结果成功随访48例患者,将治疗前后主客观指标对比,治疗4周及停药4周与治疗前相比,差异均有统计学意义(P<0.05)。治疗4周与停药后4周相比,差异均无统计学意义(P>0.05)。结论索利那新联合坦索罗辛治疗慢性前列腺炎伴OAB患者的疗效显著。

Curative Effect of Solifenacin with Tamsulosin on Overactive Bladder

Objective To explore the curative effect of solifenacin combined with tamsulosion in the treatment of chronic prostatitis with overactive bladder(OAB).Methods All 157 cases met our inclusion criteria.The patients were administrated with moxifloxacin at 0.4 g once daily for 2 weeks,tamsulosin at 0.2 mg and solifenacin at 5.0 mg once daily for 4 weeks.The curative effect was assessed by the changes in white blood cell counts in expressed prostatic secretion(EPS),overactive bladder symptom score(OABSS),NIH-Chronic Prostatitis Symptom Index(NIH-CPSI),maximum flow rate(Qmax) and voided volume before the treatment,4 weeks after the treatment and 4 weeks after drug withdrawal.Results Forty eight cases were followed up.The difference in subjective and objective indicators was significant as compared the results before the treatment with those 4 weeks after the treatment or 4 weeks after the drug withdrawal(P<0.05).There was no significant difference in the results between 4 weeks after the treatment and 4 weeks after the drug withdrawal(P>0.05).Conclusion Solifenacin combined with tamsulosin has a significant curative effect on the chronic prostatitis with overactive bladder.